Buy DXM Polistirex Powder (Dextromethorphan Polistirex) – USA & Europe

1. What is DXM Polistirex Powder?

DXM Polistirex Powder is the extended-release form of dextromethorphan, a widely used antitussive (cough suppressant). Polistirex refers to dextromethorphan bound to a polystyrene sulfonate ion-exchange resin that controls drug release over an extended period. This formulation is beneficial for sustained therapeutic effect and improved dosing compliance.

2. Chemical Composition & Structure

Dextromethorphan polistirex consists of the active pharmaceutical ingredient dextromethorphan (C18H25NO) complexed with a polystyrene sulfonate resin, making it less water-soluble and allowing slow release in the gastrointestinal tract. The active moiety has a molecular weight of approximately 271.4 g/mol.

3. Research Applications

This controlled-release powder is studied for its cough suppressant properties and its unique pharmacokinetics which provide long-lasting NMDA receptor antagonism and sigma-1 receptor agonism. It is researched for neuroprotective, analgesic, and mood-modulating effects in various clinical and experimental models.

4. Recommended Laboratory Handling & Safety Guidelines

Handle powder with gloves in well-ventilated areas. Avoid inhalation, ingestion, and skin contact. Store in airtight containers, protected from moisture, light, and heat to maintain chemical stability.

5. Hazard Warnings & Risk Statements

Classified as harmful if swallowed or inhaled. Causes irritation of respiratory tract, skin, and eyes. Strict adherence to safety data sheets (SDS) and protective measures is necessary.

6. Compatibility with Other Substances

Compatible with aqueous suspensions designed for oral extended-release formulations. Incompatible with strong oxidizers and certain solvents.

7. Emergency Protocols for Exposure

Flush skin or eyes with water in case of contact. If inhaled or ingested, seek immediate medical care.

8. Storage Stability & Shelf Life

When stored under controlled conditions (cool, dry, and dark), stability and efficacy are maintained for an extended period.

9. Licensing & Purchase

Available for research purchase subject to regulatory compliance.

10. Legality of Online Purchase

Controlled substance status varies by region; confirm legal status before acquisition.

11. Laboratory Safety Practices

Use PPE, maintain ventilation, and follow waste disposal regulations.

12. Medical Considerations

Avoid exposure in pregnancy and individuals with certain medical conditions.

13. Allergen Exposure Risk

Minimal; gloves recommended.

14. Interaction with Other Research Chemicals

Caution advised with drugs affecting CNS neurotransmitters.

15. Pregnancy and Exposure Precautions

Not recommended.

16. Handling Consistency

Precise measurement and storage protocols optimize reproducibility.

17. Optimizing Research Outcomes

Utilize pharmaceutical-grade powder with validated assay methods.

18. Pharmacological Effects Reported

Sustained cough suppression, NMDA antagonism, neuroprotection, and mood regulation.

19. Adverse Effects

May include nausea, dizziness, and hallucinations at high doses.

20. Severe Exposure Management

Immediate medical intervention is critical.

21. Solvent Use

Suitable for aqueous suspensions mimicking commercial extended-release formulations.

22. Research Scheduling

Follow strict dosing regimens for valid data.

23. Storage Duration Recommendations

Stable for several years under appropriate storage.

24. Post-Research Stability

Maintain original packaging; dispose of degraded material appropriately.

25. Dependency or Sensitization Risk

Low abuse potential but psychological sensitization possible.

26. Long-Term Storage Recommendations

Store sealed in cool, dry, protected environment.

27. Alternative Extended-Release Formulations

Other forms include dextromethorphan hydrobromide extended-release tablets.